HARVARD APPARATUS REGENERATIVE TECHNOLOGY INC.

Harvard Apparatus Regenerative Technology Inc.

Equities

HRGN

US09074M2026

Advanced Medical Equipment & Technology

Delayed OTC Markets Other stock markets 17:36:16 15/05/2024 BST			5-day change	1st Jan Change
2.68 ^USD	+15.52%		+15.52%	-46.29%

04-15	Harvard Apparatus Regenerative Technology Inc. announced that it expects to receive $1.482101 million in funding	CI
03-28	Harvard Apparatus Regenerative Technology Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Biostage, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022

May 16, 2022 at 09:05 pm

Biostage, Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported net loss was USD 2.18 million compared to USD 0.874 million a year ago. Basic loss per share from continuing operations was USD 0.2 compared to USD 0.09 a year ago.

Latest news about Harvard Apparatus Regenerative Technology Inc.

Harvard Apparatus Regenerative Technology Inc. announced that it expects to receive $1.482101 million in funding	04-14	CI
Harvard Apparatus Regenerative Technology Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Harvard Apparatus Regenerative Technology Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Transcript : Harvard Apparatus Regenerative Technology Inc., Q3 2023 Earnings Call, Nov 13, 2023	11-13
Harvard Apparatus Regenerative Technology Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Transcript : Harvard Apparatus Regenerative Technology Inc., Q2 2023 Earnings Call, Aug 14, 2023	14/08/23
Biostage, Inc. Activated Mayo Clinic as the First Site for Clinical Trial in Severe Esophageal Disease	18/07/23	CI
Transcript : Biostage, Inc. - Special Call	20/06/23
Biostage, Inc. Initiates Study Start-Up Activities for Clinical Trial in Severe Esophageal Disease	31/05/23	CI
Biostage Initiates Study Start-Up Activities for Clinical Trial in Severe Esophageal Disease	31/05/23	CI
Biostage, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
Biostage, Inc. announced that it has received $6.005802 million in funding	12/04/23	CI
Biostage, Inc. Appoints Ron Packard to Board of Directors	10/04/23	CI
Biostage, Inc. announced that it expects to receive $6.005802 million in funding	30/03/23	CI
Biostage, Inc. Auditor Raises 'Going Concern' Doubt	29/03/23	CI
Biostage, Inc Announces Board Changes	02/03/23	CI
Biostage, Inc Announces Executive Changes	02/03/23	CI
Biostage, Inc. Amends CEO Employment Agreement	12/01/23	CI
Biostage, Inc. Announces New Publication Demonstrates Rapid Esophageal Regeneration Using the Biostage Esophageal Implant	23/12/22	CI
Insider Sell: Biostage	09/12/22	MT
Transcript : Biostage, Inc., Q3 2022 Earnings Call, Nov 15, 2022	15/11/22
Biostage, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
Biostage, Inc. Announces Appointment of Joseph Damasio as New Chief Financial Officer	08/08/22	CI
Transcript : Biostage, Inc., Q2 2022 Earnings Call, Aug 05, 2022	05/08/22
Biostage, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	04/08/22	CI

Chart Harvard Apparatus Regenerative Technology Inc.

Duration

Period

Chart Harvard Apparatus Regenerative Technology Inc.

More charts

Company Profile

Harvard Apparatus Regenerative Technology, Inc. is a clinical-stage biotechnology company. It uses the patientâs own stem cells grown on a porous plastic tubular scaffold to regenerate the esophagus after it has been removed due to cancer, trauma, or birth defects. The Company is targeting the conditions of the esophagus, including traumatic injury, caustic burns, tissue damage following chemoradiation therapy and birth defects. Its additional product candidates in its development pipeline are targeted at the reconstruction of the colon and uterus wound repair. Its product candidate includes Cellspan Esophageal Implant, and Cellspan Bronchial Implants. It is developing Cellspan Esophageal Implant for the treatment of esophageal atresia. Esophageal atresia is a birth disorder of the digestive system in which the esophagus does not develop properly. Cellspan Bronchial Implants enables the surgeon to preserve the lung and repair the bronchus through various surgical resection.

Sector

Advanced Medical Equipment & Technology

Calendar

14/05/2024 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
HARVARD APPARATUS REGENERATIVE TECHNOLOGY INC.	-46.29%	33.21M
THERMO FISHER SCIENTIFIC	+12.78%	227B
DANAHER CORPORATION	+13.37%	192B
INTUITIVE SURGICAL, INC.	+18.17%	136B
BOSTON SCIENTIFIC CORPORATION	+28.28%	108B
SIEMENS HEALTHINEERS AG	+1.67%	64.07B
EDWARDS LIFESCIENCES CORPORATION	+17.76%	52.1B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+7.04%	51.87B
AGILENT TECHNOLOGIES, INC.	+10.78%	44.33B
GE HEALTHCARE TECHNOLOGIES INC.	+6.04%	36.75B

Other Advanced Medical Equipment & Technology